Corteva Valuation
Is CTVA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CTVA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CTVA (€58.39) is trading below our estimate of fair value (€64.59)
Significantly Below Fair Value: CTVA is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CTVA?
Key metric: As CTVA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is CTVA's PE Ratio? | |
|---|---|
| PE Ratio | 62.8x |
| Earnings | US$670.00m |
| Market Cap | US$42.08b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.7x |
| Enterprise Value/EBITDA | 15.1x |
| PEG Ratio | 2.3x |
Price to Earnings Ratio vs Peers
How does CTVA's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 27.3x | ||
NTR Nutrien | 31.6x | 34.8% | CA$32.4b |
WIE Wienerberger | 43.7x | 47.0% | €3.0b |
000792 Qinghai Salt Lake IndustryLtd | 18x | 10.5% | CN¥98.4b |
2020 SABIC Agri-Nutrients | 15.9x | 3.0% | ر.س53.3b |
CTVA Corteva | 62.8x | 26.8% | €42.1b |
Price-To-Earnings vs Peers: CTVA is expensive based on its Price-To-Earnings Ratio (62.8x) compared to the peer average (27.3x).
Price to Earnings Ratio vs Industry
How does CTVA's PE Ratio compare vs other companies in the European Chemicals Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: CTVA is expensive based on its Price-To-Earnings Ratio (62.8x) compared to the European Chemicals industry average (16.9x).
Price to Earnings Ratio vs Fair Ratio
What is CTVA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 62.8x |
| Fair PE Ratio | 34x |
Price-To-Earnings vs Fair Ratio: CTVA is expensive based on its Price-To-Earnings Ratio (62.8x) compared to the estimated Fair Price-To-Earnings Ratio (34x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €58.39 | €62.66 +7.3% | 6.9% | €67.73 | €54.38 | n/a | 22 |
| Nov ’25 | €56.28 | €59.21 +5.2% | 7.6% | €64.72 | €50.85 | n/a | 22 |
| Oct ’25 | €52.94 | €56.80 +7.3% | 7.3% | €62.98 | €49.48 | n/a | 22 |
| Sep ’25 | €51.50 | €56.80 +10.3% | 7.3% | €62.98 | €49.48 | n/a | 22 |
| Aug ’25 | €50.17 | €58.64 +16.9% | 6.5% | €64.87 | €51.90 | n/a | 21 |
| Jul ’25 | €49.54 | €58.90 +18.9% | 6.8% | €65.20 | €50.30 | n/a | 21 |
| Jun ’25 | €50.74 | €58.67 +15.6% | 6.8% | €64.53 | €49.78 | n/a | 20 |
| May ’25 | €51.00 | €58.46 +14.6% | 7.5% | €65.58 | €49.65 | n/a | 23 |
| Apr ’25 | €53.70 | €57.20 +6.5% | 7.7% | €64.89 | €49.13 | n/a | 23 |
| Mar ’25 | €50.20 | €57.03 +13.6% | 7.4% | €64.76 | €49.04 | n/a | 24 |
| Feb ’25 | €48.85 | €54.44 +11.5% | 9.9% | €64.40 | €46.00 | n/a | 24 |
| Jan ’25 | €43.50 | €53.70 +23.4% | 9.6% | €65.36 | €45.52 | n/a | 24 |
| Dec ’24 | €42.40 | €53.70 +26.7% | 9.6% | €65.36 | €45.52 | n/a | 24 |
| Nov ’24 | €45.15 | €61.88 +37.0% | 10.7% | €77.24 | €49.92 | €56.28 | 23 |
| Oct ’24 | €48.65 | €65.04 +33.7% | 8.2% | €77.42 | €53.82 | €52.94 | 22 |
| Sep ’24 | €47.35 | €63.46 +34.0% | 8.3% | €75.40 | €52.41 | €51.50 | 22 |
| Aug ’24 | €51.20 | €63.13 +23.3% | 8.3% | €74.13 | €51.53 | €50.17 | 23 |
| Jul ’24 | €52.20 | €65.50 +25.5% | 7.2% | €75.13 | €55.89 | €49.54 | 23 |
| Jun ’24 | €49.75 | €66.89 +34.4% | 7.8% | €80.86 | €56.69 | €50.74 | 22 |
| May ’24 | €54.50 | €66.50 +22.0% | 8.1% | €79.37 | €54.74 | €51.00 | 21 |
| Apr ’24 | €55.54 | €68.53 +23.4% | 7.8% | €81.58 | €56.26 | €53.70 | 21 |
| Mar ’24 | €58.74 | €68.03 +15.8% | 8.1% | €81.21 | €56.00 | €50.20 | 21 |
| Feb ’24 | €58.92 | €67.20 +14.0% | 7.7% | €79.95 | €56.98 | €48.85 | 21 |
| Jan ’24 | €55.18 | €68.29 +23.8% | 7.8% | €82.09 | €58.50 | €43.50 | 20 |
| Dec ’23 | €63.12 | €68.95 +9.2% | 8.0% | €82.65 | €58.90 | €42.40 | 20 |
| Nov ’23 | €67.88 | €71.65 +5.6% | 6.8% | €81.77 | €62.35 | €45.15 | 20 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Freeport-McMoRan
US$62.9b
Engages in the mining of mineral properties in North America, South America, and Indonesia.
FCX
US$41.78
7D
2.4%
1Y
23.7%
Akzo Nobel
€9.5b
Engages in the production and sale of paints and coatings worldwide.
AKZO
€55.98
7D
-0.4%
1Y
-19.3%
LANXESS
€2.0b
Operates as a specialty chemicals company that engages in the development, manufacture, and marketing of chemical intermediates, additives, specialty chemicals, and consumer protection products worldwide.
LXS
€23.12
7D
-3.4%
1Y
2.0%